Merck names Robert Davis new CFO
This article was originally published in Scrip
Executive Summary
Merck & Co has named Robert M Davis executive vice-president and chief financial officer – effective 23 April 2014. Mr Davis will succeed Peter N Kellogg, who has been CFO at the company since 2007. Mr Kellogg will depart from the company on 16 May 2014. To ensure a smooth transition, he will oversee the closing and reporting of the company's first quarter sales and earnings on 29 April 2014.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.